252 related articles for article (PubMed ID: 18457819)
1. Microglial activation in brain lesions with tau deposits: comparison of human tauopathies and tau transgenic mice TgTauP301L.
Sasaki A; Kawarabayashi T; Murakami T; Matsubara E; Ikeda M; Hagiwara H; Westaway D; George-Hyslop PS; Shoji M; Nakazato Y
Brain Res; 2008 Jun; 1214():159-68. PubMed ID: 18457819
[TBL] [Abstract][Full Text] [Related]
2. Partial reduction of microglia does not affect tau pathology in aged mice.
Bennett RE; Bryant A; Hu M; Robbins AB; Hopp SC; Hyman BT
J Neuroinflammation; 2018 Nov; 15(1):311. PubMed ID: 30413160
[TBL] [Abstract][Full Text] [Related]
3. Analysis of the cholinergic pathology in the P301L tau transgenic pR5 model of tauopathy.
Köhler C; Bista P; Götz J; Schröder H
Brain Res; 2010 Aug; 1347():111-24. PubMed ID: 20513372
[TBL] [Abstract][Full Text] [Related]
4. Deficiency of terminal complement pathway inhibitor promotes neuronal tau pathology and degeneration in mice.
Britschgi M; Takeda-Uchimura Y; Rockenstein E; Johns H; Masliah E; Wyss-Coray T
J Neuroinflammation; 2012 Sep; 9():220. PubMed ID: 22989354
[TBL] [Abstract][Full Text] [Related]
5. Reactive microglia drive tau pathology and contribute to the spreading of pathological tau in the brain.
Maphis N; Xu G; Kokiko-Cochran ON; Jiang S; Cardona A; Ransohoff RM; Lamb BT; Bhaskar K
Brain; 2015 Jun; 138(Pt 6):1738-55. PubMed ID: 25833819
[TBL] [Abstract][Full Text] [Related]
6. In Vivo Visualization of Tau Accumulation, Microglial Activation, and Brain Atrophy in a Mouse Model of Tauopathy rTg4510.
Ishikawa A; Tokunaga M; Maeda J; Minamihisamatsu T; Shimojo M; Takuwa H; Ono M; Ni R; Hirano S; Kuwabara S; Ji B; Zhang MR; Aoki I; Suhara T; Higuchi M; Sahara N
J Alzheimers Dis; 2018; 61(3):1037-1052. PubMed ID: 29332041
[TBL] [Abstract][Full Text] [Related]
7. The CNS in inbred transgenic models of 4-repeat Tauopathy develops consistent tau seeding capacity yet focal and diverse patterns of protein deposition.
Eskandari-Sedighi G; Daude N; Gapeshina H; Sanders DW; Kamali-Jamil R; Yang J; Shi B; Wille H; Ghetti B; Diamond MI; Janus C; Westaway D
Mol Neurodegener; 2017 Oct; 12(1):72. PubMed ID: 28978354
[TBL] [Abstract][Full Text] [Related]
8. Phosphorylated mitogen-activated protein kinase (MAPK/ERK-P), protein kinase of 38 kDa (p38-P), stress-activated protein kinase (SAPK/JNK-P), and calcium/calmodulin-dependent kinase II (CaM kinase II) are differentially expressed in tau deposits in neurons and glial cells in tauopathies.
Ferrer I; Blanco R; Carmona M; Puig B
J Neural Transm (Vienna); 2001; 108(12):1397-415. PubMed ID: 11810404
[TBL] [Abstract][Full Text] [Related]
9. Pazopanib Reduces Phosphorylated Tau Levels and Alters Astrocytes in a Mouse Model of Tauopathy.
Javidnia M; Hebron ML; Xin Y; Kinney NG; Moussa CE
J Alzheimers Dis; 2017; 60(2):461-481. PubMed ID: 28869476
[TBL] [Abstract][Full Text] [Related]
10. A novel transgenic mouse expressing double mutant tau driven by its natural promoter exhibits tauopathy characteristics.
Rosenmann H; Grigoriadis N; Eldar-Levy H; Avital A; Rozenstein L; Touloumi O; Behar L; Ben-Hur T; Avraham Y; Berry E; Segal M; Ginzburg I; Abramsky O
Exp Neurol; 2008 Jul; 212(1):71-84. PubMed ID: 18490011
[TBL] [Abstract][Full Text] [Related]
11. Genetically enhancing the expression of chemokine domain of CX
Bemiller SM; Maphis NM; Formica SV; Wilson GN; Miller CM; Xu G; Kokiko-Cochran ON; Kim KW; Jung S; Cannon JL; Crish SD; Cardona AE; Lamb BT; Bhaskar K
J Neuroinflammation; 2018 Sep; 15(1):278. PubMed ID: 30253780
[TBL] [Abstract][Full Text] [Related]
12. Organotypic brain slice cultures of adult transgenic P301S mice--a model for tauopathy studies.
Mewes A; Franke H; Singer D
PLoS One; 2012; 7(9):e45017. PubMed ID: 22984603
[TBL] [Abstract][Full Text] [Related]
13. Age-dependent effects of microglial inhibition in vivo on Alzheimer's disease neuropathology using bioactive-conjugated iron oxide nanoparticles.
Glat M; Skaat H; Menkes-Caspi N; Margel S; Stern EA
J Nanobiotechnology; 2013 Sep; 11():32. PubMed ID: 24059692
[TBL] [Abstract][Full Text] [Related]
14. Endogenous tau aggregates in oligodendrocytes of rTg4510 mice induced by human P301L tau.
Ren Y; Lin WL; Sanchez L; Ceballos C; Polydoro M; Spires-Jones TL; Hyman BT; Dickson DW; Sahara N
J Alzheimers Dis; 2014; 38(3):589-600. PubMed ID: 24028867
[TBL] [Abstract][Full Text] [Related]
15. Soluble phospho-tau from Alzheimer's disease hippocampus drives microglial degeneration.
Sanchez-Mejias E; Navarro V; Jimenez S; Sanchez-Mico M; Sanchez-Varo R; Nuñez-Diaz C; Trujillo-Estrada L; Davila JC; Vizuete M; Gutierrez A; Vitorica J
Acta Neuropathol; 2016 Dec; 132(6):897-916. PubMed ID: 27743026
[TBL] [Abstract][Full Text] [Related]
16. Genetic background modifies neurodegeneration and neuroinflammation driven by misfolded human tau protein in rat model of tauopathy: implication for immunomodulatory approach to Alzheimer's disease.
Stozicka Z; Zilka N; Novak P; Kovacech B; Bugos O; Novak M
J Neuroinflammation; 2010 Oct; 7():64. PubMed ID: 20937161
[TBL] [Abstract][Full Text] [Related]
17. Microglial activation arises after aggregation of phosphorylated-tau in a neuron-specific P301S tauopathy mouse model.
van Olst L; Verhaege D; Franssen M; Kamermans A; Roucourt B; Carmans S; Ytebrouck E; van der Pol SMA; Wever D; Popovic M; Vandenbroucke RE; Sobrino T; Schouten M; de Vries HE
Neurobiol Aging; 2020 May; 89():89-98. PubMed ID: 32008854
[TBL] [Abstract][Full Text] [Related]
18. Differential induction and spread of tau pathology in young PS19 tau transgenic mice following intracerebral injections of pathological tau from Alzheimer's disease or corticobasal degeneration brains.
Boluda S; Iba M; Zhang B; Raible KM; Lee VM; Trojanowski JQ
Acta Neuropathol; 2015 Feb; 129(2):221-37. PubMed ID: 25534024
[TBL] [Abstract][Full Text] [Related]
19. Imaging of tau pathology in a tauopathy mouse model and in Alzheimer patients compared to normal controls.
Maruyama M; Shimada H; Suhara T; Shinotoh H; Ji B; Maeda J; Zhang MR; Trojanowski JQ; Lee VM; Ono M; Masamoto K; Takano H; Sahara N; Iwata N; Okamura N; Furumoto S; Kudo Y; Chang Q; Saido TC; Takashima A; Lewis J; Jang MK; Aoki I; Ito H; Higuchi M
Neuron; 2013 Sep; 79(6):1094-108. PubMed ID: 24050400
[TBL] [Abstract][Full Text] [Related]
20. Phosphorylated p38MAPK specific antibodies cross-react with sarkosyl-insoluble hyperphosphorylated tau proteins.
Sahara N; Vega IE; Ishizawa T; Lewis J; McGowan E; Hutton M; Dickson D; Yen SH
J Neurochem; 2004 Aug; 90(4):829-38. PubMed ID: 15287888
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
